Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

Home
/
update
/
details

Bayer and AskBio Partner with Belief BioMed to Develop Liver-Targeted Gene Therapies

NextEdge Admin

27 Sep 2024

2 min 22 sec

Bayer AG and its gene therapy subsidiary, Asklepios BioPharmaceutical, Inc. (AskBio), have announced a strategic collaboration with Belief BioMed Inc. (BBM) to explore liver-targeted gene therapies for various diseases. This partnership will leverage both companies' expertise to develop innovative treatments for conditions that could be addressed through this approach.

Mansuo Shannon, Chief Scientific Officer at AskBio, emphasized the company's focus on global collaboration to advance gene therapy, highlighting the potential of BBM's next-generation capsid technology. These novel adeno-associated virus (AAV) vectors have demonstrated reduced immunogenicity and improved transduction efficiency in both human and non-human trials compared to conventional AAV vectors. BBM, headquartered in Shanghai, integrates research, development, manufacturing, and clinical application of gene therapies, with a particular focus on serious genetic and chronic diseases. In July, BBM’s New Drug Application (NDA) for a gene therapy targeting hemophilia B was accepted by China's National Medical Products Administration, marking the first NDA submission in China for a gene therapy for an inborn genetic disease.

Gustavo Pesquin, CEO of AskBio, highlighted the significance of this partnership, noting the important contributions of BBM's Chairman and Chief Scientific Officer, Dr. Xiao, a co-founder of AskBio. He emphasized how collaborations with innovative partners like BBM strengthen the development pipeline. Juergen Eckhardt, Head of Business Development & Licensing at Bayer, added that gene therapy holds immense potential, and partnerships like this one are crucial for advancing treatments that address significant unmet medical needs.